{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:39:02Z","timestamp":1790314742870,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2021\/097\/Startup\/13"],"award-info":[{"award-number":["NUHSRO\/2021\/097\/Startup\/13"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07584-6","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:29:43Z","timestamp":1761287383000},"page":"2351-2361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u00b9\u2078F-AlF-NOTA-octreotide PET\/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with \u00b9\u2078F-FDG PET\/CT"],"prefix":"10.1007","volume":"53","author":[{"given":"Guozhu","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihebali","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"7584_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"key":"7584_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1530\/erc-13-0027","volume":"20","author":"FL V\u00e9layoudom-C\u00e9phise","year":"2013","unstructured":"V\u00e9layoudom-C\u00e9phise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20:649\u201357. https:\/\/doi.org\/10.1530\/erc-13-0027.","journal-title":"Endocr Relat Cancer"},{"key":"7584_CR3","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.23469","volume":"112","author":"I Kayani","year":"2008","unstructured":"Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447\u201355. https:\/\/doi.org\/10.1002\/cncr.23469.","journal-title":"Cancer"},{"issue":"10","key":"7584_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/mnm.0000000000001255","volume":"41","author":"H You","year":"2020","unstructured":"You H, Kandathil A, Beg M, De Blanche L, Kazmi S, Subramaniam RM. Ga-68 DOTATATE PET\/CT and F-18 FDG PET\/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. Nucl Med Commun. 2020;41(10):1060\u20135. https:\/\/doi.org\/10.1097\/mnm.0000000000001255.","journal-title":"Nucl Med Commun"},{"key":"7584_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI procedure standard\/eanm practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med. 2023;64:204\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264860.","journal-title":"J Nucl Med"},{"key":"7584_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/jnumed.118.215848","volume":"60","author":"J Zhang","year":"2019","unstructured":"Zhang J, Kulkarni HR, Singh A, Niepsch K, M\u00fcller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60:377\u201385. https:\/\/doi.org\/10.2967\/jnumed.118.215848.","journal-title":"J Nucl Med"},{"key":"7584_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00259-017-3925-8","volume":"45","author":"S Nicolini","year":"2018","unstructured":"Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, et al. Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018;45:923\u201330. https:\/\/doi.org\/10.1007\/s00259-017-3925-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7584_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","volume":"45","author":"SP Thang","year":"2018","unstructured":"Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, et al. Peptide receptor radionuclide therapy (PRRT) in European neuroendocrine tumour society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45:262\u201377. https:\/\/doi.org\/10.1007\/s00259-017-3821-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7584_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/erc-18-0424","volume":"26","author":"EA Carlsen","year":"2019","unstructured":"Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26:227\u201339. https:\/\/doi.org\/10.1530\/erc-18-0424.","journal-title":"Endocr Relat Cancer"},{"key":"7584_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/s0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/s0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"7584_CR11","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.7150\/thno.96762","volume":"14","author":"G Hou","year":"2024","unstructured":"Hou G, Cheng X, Yang Y, Zhao D, Wang G, Zhao H, et al. Diagnostic performance and clinical impact of (18)F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: a prospective single-center study. Theranostics. 2024;14:3213\u201320. https:\/\/doi.org\/10.7150\/thno.96762.","journal-title":"Theranostics"},{"key":"7584_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. (18)F-AlF-NOTA-Octreotide outperforms (68)Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2023;64:632\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264563.","journal-title":"J Nucl Med"},{"key":"7584_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01003-3","volume":"13","author":"L Boeckxstaens","year":"2023","unstructured":"Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, et al. Prospective comparison of [(18)F]AlF-NOTA-octreotide PET\/MRI to [(68)Ga]Ga-DOTATATE PET\/CT in neuroendocrine tumor patients. EJNMMI Res. 2023;13:53. https:\/\/doi.org\/10.1186\/s13550-023-01003-3.","journal-title":"EJNMMI Res"},{"key":"7584_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.115.156539","volume":"56","author":"A Pfeifer","year":"2015","unstructured":"Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847\u201354. https:\/\/doi.org\/10.2967\/jnumed.115.156539.","journal-title":"J Nucl Med"},{"key":"7584_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/jco.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting Gastro-Entero-Pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34:588\u201396. https:\/\/doi.org\/10.1200\/jco.2015.64.0987.","journal-title":"J Clin Oncol"},{"key":"7584_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000368609","volume":"100","author":"S Partelli","year":"2014","unstructured":"Partelli S, Rinzivillo M, Maurizi A, Panzuto F, Salgarello M, Polenta V, et al. The role of combined Ga-DOTANOC and (18)FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology. 2014;100:293\u20139. https:\/\/doi.org\/10.1159\/000368609.","journal-title":"Neuroendocrinology"},{"key":"7584_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, et al. (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-Year follow-up study. J Nucl Med. 2021;62:808\u201315. https:\/\/doi.org\/10.2967\/jnumed.120.244798.","journal-title":"J Nucl Med"},{"key":"7584_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13359","volume":"36","author":"V Ambrosini","year":"2024","unstructured":"Ambrosini V, Caplin M, Casta\u00f1o JP, Christ E, Denecke T, Deroose CM, et al. Use and perceived utility of [(18) F]FDG PET\/CT in neuroendocrine neoplasms: a consensus report from the European neuroendocrine tumor society (ENETS) advisory board meeting 2022. J Neuroendocrinol. 2024;36:e13359. https:\/\/doi.org\/10.1111\/jne.13359.","journal-title":"J Neuroendocrinol"},{"key":"7584_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13249","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35:e13249. https:\/\/doi.org\/10.1111\/jne.13249.","journal-title":"J Neuroendocrinol"},{"key":"7584_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13306","volume":"35","author":"F Panzuto","year":"2023","unstructured":"Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J, Begum N, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J Neuroendocrinol. 2023;35:e13306. https:\/\/doi.org\/10.1111\/jne.13306.","journal-title":"J Neuroendocrinol"},{"key":"7584_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2967\/jnumed.114.142224","volume":"55","author":"D Has Simsek","year":"2014","unstructured":"Has Simsek D, Kuyumcu S, Turkmen C, Sanl\u0131 Y, Aykan F, Unal S, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET\/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014;55:1811\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.142224.","journal-title":"J Nucl Med"},{"key":"7584_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149\u201358. https:\/\/doi.org\/10.7150\/thno.18068.","journal-title":"Theranostics"},{"key":"7584_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Furtado O\u2019Mahony L, Mileva M, et al. Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128:549\u201355. https:\/\/doi.org\/10.1038\/s41416-022-02061-5.","journal-title":"Br J Cancer"},{"key":"7584_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2967\/jnumed.124.267982","volume":"65","author":"U Metser","year":"2024","unstructured":"Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, et al. Dual somatostatin receptor\/(18)F-FDG PET\/CT imaging in patients with well-differentiated, grade 2 and 3 gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2024;65:1591\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267982.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07584-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:23Z","timestamp":1771479503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7584"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07584-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered at ClinicalTrials.gov (NCT05749289) and received ethical approval from the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences (Approval No. 22\/480\u20133682). All procedures were conducted in accordance with the ethical standards of the institutional research committee, the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects gave written consent before participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that all human participants involved in this study have signed the consent form and agreed to the publication of their medical imaging and records in an anonymized format for the purposes of scientific research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}